한글목차

세계의 중합효소 연쇄 반응 시장 규모는 2024년에 82억 달러에 달했습니다. 향후 IMARC Group은 시장이 2033년까지 144억 달러에 달하며, 2025-2033년의 성장률(CAGR)은 6.18%에 달할 것으로 예측하고 있습니다.

중합효소연쇄반응(PCR)은 DNA 부문의 복수의 사본을 생성하는 데 사용되는 분자진단 기술입니다. PCR 장비는 사전 프로그래밍된 자동 절차에 따라 시료의 온도를 조작하고 수백만 개의 DNA 염기서열 사본을 정확하게 생성하는 데 사용됩니다. 이 기술은 병원성 미생물을 식별하고 배양하여 결핵, 후천성면역결핍증후군(AIDS), 감염성 질환, 라임병 검출에 도움이 됩니다. 따라서 유전학, 생명공학, 분자생물학, 신약개발, 임상진단 등 다양한 생명과학 관련 분야에 폭넓게 적용되고 있습니다.

중합효소 연쇄반응 시장 동향 및 촉진요인

다양한 감염성 질환 및 유전성 질환의 유병률 증가는 시장 성장을 가속하는 주요 요인 중 하나입니다. 또한 만성질환에 취약한 노인 인구가 전 세계에서 증가하고 있는 것도 시장 성장을 가속하고 있습니다. 코로나바이러스(COVID-19)의 대유행은 정확한 진단과 감염의 조기 발견을 위한 PCR 기술의 보급을 더욱 촉진하고 있습니다. PCR 장비는 또한 오염의 위험과 전체 공정에서 인위적인 실수의 가능성을 최소화하는 데 도움이 됩니다.

맞춤형 의료와 정밀의료에 대한 수요 증가도 시장 전망을 밝게 하고 있습니다. 이들 의약품은 PCR 기술을 통해 식별되고 개발되는 맞춤형 치료제를 제공하는 것을 목표로 하고 있습니다. 이 외에도 임상 진단 분야에서의 사용 증가, 생명공학 분야의 광범위한 연구개발(R&D) 활동 등이 시장을 더욱 견인할 것으로 예측됩니다.

이 보고서에서 다룬 주요 질문

• 세계 중합효소 연쇄반응 시장은 지금까지 어떻게 성장하며 왔으며, 향후 수년간 어떻게 성장하는가?
• COVID-19가 세계 중합효소 연쇄반응 시장에 미친 영향은?
• 주요 지역 시장은?
• 제품별 시장 분석은?
• 최종사용자별 시장 분석은?
• 산업 밸류체인의 다양한 단계는?
• 업계의 주요 촉진요인과 과제는?
• 세계 중합효소 연쇄반응 시장의 구조와 주요 업체는?
• 업계내 경쟁은 어느 정도인가?

목차

제1장 서문

제2장 조사 범위와 조사 방법

• 조사의 목적
• 이해관계자
• 데이터 소스
  • 1차 정보
  • 2차 정보
• 시장 추정
  • 보텀업 어프로치
  • 톱다운 어프로치
• 조사 방법

제3장 개요

제4장 서론

제5장 세계의 중합효소 연쇄 반응 시장

• 시장 개요
• 시장 실적
• COVID-19의 영향
• 시장 예측

제6장 시장 내역 : 제품별

• 기기
  • 유형별
    • 표준 PCR 시스템
    • 디지털 PCR 시스템
    • 실시간 PCR 시스템
• 시약·소모품
• 소프트웨어·서비스

제7장 시장 내역 : 최종사용자별

• 학술연구기관
• 임상 진단 실험실·병원
• 제약·바이오테크놀러지 기업
• 기타

제8장 시장 내역 : 지역별

• 북미
  • 미국
  • 캐나다
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 인도네시아
  • 기타
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 러시아
  • 기타
• 라틴아메리카
  • 브라질
  • 멕시코
  • 기타
• 중동 및 아프리카

제9장 SWOT 분석

제10장 밸류체인 분석

제11장 Porter's Five Forces 분석

제12장 가격 분석

제13장 경쟁 구도

• 시장 구조
• 주요 기업
• 주요 기업의 개요
  • Agilent Technologies Inc.
  • BD(Becton, Dickinson and Company)
  • BioMerieux(Institut Merieux SA)
  • Bio-RAD Laboratories Inc.
  • F. Hoffmann-La Roche AG
  • Fluidigm Corporation
  • Merck KGaA
  • Perkinelmer Inc.
  • Promega Corporation
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.

영문목차

The global polymerase chain reaction market size reached USD 8.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 14.4 Billion by 2033, exhibiting a growth rate (CAGR) of 6.18% during 2025-2033.

Polymerase chain reaction (PCR) refers to a molecular diagnostic technique that is used to make multiple copies of a segment of DNA. A PCR machine is used to manipulate the temperature of the sample in an automatic and pre-programmed procedure to generate millions of copies of DNA sequencing accurately. This technology identifies and cultures disease-causing microorganisms, which aid in the detection of tuberculosis, Acquired Immunodeficiency Syndrome (AIDS), infections and Lyme disease. Owing to this, it finds extensive applications across various life science-related fields, such as genetics, biotechnology, molecular biology, drug discovery and clinical diagnostics.

Global Polymerase Chain Reaction Market Trends and Drivers:

The increasing prevalence of various infectious diseases and genetic disorders is one of the key factors driving the growth of the market. The rising geriatric population across the globe, which is more prone to chronic medical ailments, is also driving the industry growth. The outbreak of the coronavirus disease (COVID-19) pandemic has further led to the widespread adoption of PCR technologies for accurate diagnosis and early detection of infections. PCR devices also aid in minimizing the risks of contamination and the chances of human errors in the entire process.

The increasing demand for personalized and precision medicines is also creating a positive outlook for the market. These medicines aim to provide tailor-made therapies, which are identified and developed using PCR technologies. Other factors, including the increasing application in clinical diagnostics, along with extensive research and development (R&D) activities in the field of biotechnology, are expected to drive the market further.

Key Market Segmentation:

Breakup by Product:

• Instruments
  • Standard PCR Systems
  • Digital PCR Systems
  • Real-Time PCR Systems
• Reagents and Consumables
• Software and Services

Breakup by End User:

• Academic and Research Institutes
• Clinical Diagnostics Labs and Hospitals
• Pharmaceutical and Biotechnology Companies
• Others

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies Inc., BD (Becton, Dickinson and Company), BioMerieux (Institut Merieux SA), Bio-RAD Laboratories Inc., F. Hoffmann-La Roche AG, Fluidigm Corporation, Merck KGaA, Perkinelmer Inc., Promega Corporation, Takara Bio Inc. and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

• How has the global polymerase chain reaction market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global polymerase chain reaction market?
• What are the key regional markets?
• What is the breakup of the market based on the product?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global polymerase chain reaction market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Polymerase Chain Reaction Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Instruments
  • 6.1.1 Market Trends
  • 6.1.2 Market Breakup by Type
    • 6.1.2.1 Standard PCR Systems
      • 6.1.2.1.1 Market Trends
      • 6.1.2.1.2 Market Forecast
    • 6.1.2.2 Digital PCR Systems
      • 6.1.2.2.1 Market Trends
      • 6.1.2.2.2 Market Forecast
    • 6.1.2.3 Real-Time PCR Systems
      • 6.1.2.3.1 Market Trends
      • 6.1.2.3.2 Market Forecast
  • 6.1.3 Market Forecast
• 6.2 Reagents and Consumables
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Software and Services
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by End User

• 7.1 Academic and Research Institutes
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Clinical Diagnostics Labs and Hospitals
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Pharmaceutical and Biotechnology Companies
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Agilent Technologies Inc.
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 BD (Becton, Dickinson and Company)
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
    • 13.3.2.4 SWOT Analysis
  • 13.3.3 BioMerieux (Institut Merieux SA)
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
    • 13.3.3.4 SWOT Analysis
  • 13.3.4 Bio-RAD Laboratories Inc.
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 F. Hoffmann-La Roche AG
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
  • 13.3.6 Fluidigm Corporation
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
  • 13.3.7 Merck KGaA
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
    • 13.3.7.4 SWOT Analysis
  • 13.3.8 Perkinelmer Inc.
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis
  • 13.3.9 Promega Corporation
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
  • 13.3.10 Takara Bio Inc.
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 Financials
  • 13.3.11 Thermo Fisher Scientific Inc.
    • 13.3.11.1 Company Overview
    • 13.3.11.2 Product Portfolio
    • 13.3.11.3 Financials
    • 13.3.11.4 SWOT Analysis